Description:
Niraparib is an inhibitor of PARP, which was approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- Molecular Weight: 320.396
- Molecular Formula: C19H20N4O
Canonical SMILES:
C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
InChI:
InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
InChIKey: PCHKPVIQAHNQLW-CQSZACIVSA-N- Boiling Point: 463.6±45.0 °C at 760 mmHg
- Appearance: Light Yellow Solid
Synonyms:
MK-4827; MK 4827; MK4827; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; ZEJULA; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
More details are to be found on supplier website
